Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel
- 20 April 2010
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 46 (11) , 2027-2035
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial dataThe Lancet Oncology, 2009
- Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate CancerClinical Cancer Research, 2008
- The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapyThis article is one of a selection of papers published in the special issue (part 2 of 2) on Forefronts in Endothelin.Canadian Journal of Physiology and Pharmacology, 2008
- Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate CancerNew England Journal of Medicine, 2004
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerNew England Journal of Medicine, 2004
- Quantification of angiogenesis as a prognostic marker in human carcinomasEuropean Journal of Cancer, 2003
- ABT-627, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma growth in vitroClinical Science, 2002
- Endothelin-1 Induces Vascular Endothelial Growth Factor by Increasing Hypoxia-inducible Factor-1α in Ovarian Carcinoma CellsJournal of Biological Chemistry, 2002
- Increased endothelin-1 in colorectal cancer and reduction of tumour growth by ET A receptor antagonismBritish Journal of Cancer, 2001